Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone OK'd to Start China Trials of Third I-O Candidate

publication date: Aug 28, 2018

CStone Pharma, a two-year old Shanghai-Suzhou biopharma, reported the CNDA approved its IND application for CS1002, a CTLA-4 monoclonal antibody. With the approval, CStone claims to be the only China biopharma with clinical trials underway of all three major immuno-oncology products -- PD-L1, PD-1 and CTLA-4. In May, CStone announced a record-breaking $260 million Series B financing. The company is currently developing a portfolio of 14 oncology drugs, eight of them in clinical development and three in registration trials. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital